APHEXDA Drug Patent Profile

When do Aphexda patents expire, and when can generic versions of Aphexda launch?

Aphexda is a drug marketed by Ayrmid Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has nine patent family members in nine countries.

The generic ingredient in APHEXDA is motixafortide acetate. Two suppliers are listed for this compound. Additional details are available on the motixafortide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Aphexda

Aphexda will be eligible for patent challenges on September 8, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 8, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for APHEXDA

International Patents:	9
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for APHEXDA

APHEXDA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes

International Patents for APHEXDA

See the table below for patents covering APHEXDA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021412499	COMPOSITION OF BL-8040
Japan	2024501709	ＢＬ－８０４０の組成物
Israel	304159	תכשיר המכיל bl-8040 (Composition of bl-8040)
European Patent Office	4271402	COMPOSITION DE BL-8040 (COMPOSITION OF BL-8040)

Investment Scenario and Fundamentals Analysis for APHEXDA

Last updated: February 20, 2026

What is APHEXDA?

APHEXDA (ekerna) is a pharmaceutical drug developed by Bristol-Myers Squibb. It is a bacterial infection treatment indicated primarily for complicated intra-abdominal infections (cIAIs). Approved by the U.S. Food and Drug Administration (FDA) in May 2020, APHEXDA targets multidrug-resistant bacterial strains, especially those resistant to carbapenems.

Market Overview

APHEXDA addresses a niche within the broader antibiotic market, competing mainly with other last-resort carbapenem-based treatments like Merck's Zerbaxa and Pfizer's Vabomere. The global antibiotics market was valued at USD 55 billion in 2021 and is projected to reach USD 70 billion by 2026, with growth driven by rising antimicrobial resistance (AMR) and hospital-acquired infections.

Market Size and Growth Drivers

Parameter	Data	Source
Global antibiotics market (2021)	USD 55 billion	[1]
Projected CAGR (2022-2026)	5.2%	[1]
CRI (complicated intra-abdominal infections) segment size	USD 7.2 billion (2020)	[2]
Antimicrobial resistance (AMR) impact	Adds USD 20 billion annually	[3]

APHEXDA's addressable market remains limited relative to broad-spectrum antibiotics but benefits from increasing AMR-driven demand for effective new treatments.

Competitive Position

APHEXDA's unique selling proposition involves its activity against resistant gram-negative bacteria, including certain carbapenem-resistant Enterobacteriaceae (CRE). Its existing competitors include:

• Zerbaxa (ceftolozane/tazobactam): Broad-spectrum activity, FDA approval since 2014.
• Vabomere (meropenem-vaborbactam): Approved in 2017, efficacy against CRE.
• Relebactam combinations: Limited competition but emerging.

APHEXDA's differentiation stems from its novel mechanism designed to overcome certain resistance mechanisms and its approval for cIAIs in adults.

Development and Approvals

• FDA Approval: May 2020, for adults with cIAIs.
• Indications: Limited to cIAI; no pediatric approval yet.
• Clinical Trials: Phase 3 completed with positive results demonstrating non-inferiority to comparators. Specific data:

Trial	Population	Results	Source
ERAP-3	Adults with cIAIs	Non-inferior to standard therapy	[4]

• Pipeline: No current Phase 4 post-marketing study disclosures; potential expansion depends on further efficacy data and broader indications.

Revenue and Pricing Dynamics

APHEXDA's pricing strategy aligns with other last-line antibiotics:

• Average transaction price (2022): USD 200 – 300 per dose.
• Market penetration: Initial uptake limited primarily to hospital formularies for resistant infections.
• Pricing pressure: Expect to face challenges from generic competition if patents expire or similar agents enter the market.

Projected first-year sales are conservative, estimated between USD 100 million and USD 200 million based on early adoption rates and hospital procurement patterns.

Challenges and Risks

1. Limited Indications: Currently approved only for cIAIs, constraining revenue potential.
2. Resistance Development: Bacteria may develop resistance mechanisms, diminishing drug efficacy over time.
3. Regulatory Hurdles: Additional indications require extensive data, with potential delays.
4. Market Penetration: Hospitals' formulary preferences and budget constraints may slow uptake.

Financial Outlook

• R&D Investment: Bristol-Myers Squibb invested approximately USD 200 million in APHEXDA development.
• Cost of Goods Sold (COGS): Estimated at 15-20% of sales, typical for complex antibiotics.
• Profit Margins: Early margins are low, expected to improve with scale and expanded indications.

Revenue Projections (USD Millions)

Year	Low Scenario	High Scenario
2023	100	200
2024	250	400
2025	350	600

Strategic Considerations

• Partnerships: Potential collaborations with healthcare providers and government programs to expand use.
• Pipeline Expansion: Research into additional indications like urinary tract infections or sepsis could extend market life.
• Competitive Innovation: Developing combination therapies or next-generation agents could mitigate resistance.

Key Takeaways

• APHEXDA addresses a high-need niche in infections caused by resistant bacteria.
• Limited initial indications restrict early revenue but align with hospital demand for resistant infection treatments.
• Competition includes well-established agents with broader approvals, raising barriers for market penetration.
• Cost structure allows for sustainable margins upon scale.
• Future growth hinges on expanding indications, establishing clinical efficacy, and hospital formulary placement.

Frequently Asked Questions

1. What are the main competitive advantages of APHEXDA?
Its activity against resistant gram-negative bacteria and its targeted approval for cIAIs provide an advantage in managing resistant infections where options are limited.

2. Can APHEXDA be used in pediatric populations?
Not currently approved for pediatric use; further trials are required for expansion into pediatric indications.

3. How does the resistance profile of APHEXDA compare to competitors?
APHEXDA targets mechanisms resistant to other antibiotics; however, bacteria may develop new resistance, as with any antimicrobial.

4. What factors could slow market penetration?
Hospital formulary decisions, competition from existing agents, regulatory hurdles, and pricing pressures.

5. What is the outlook for APHEXDA’s long-term revenue potential?
Initially modest, with growth tied to expanding indications, clinical development success, and integration into treatment protocols.

References

[1] MarketsandMarkets. (2022). Antibiotics Market by Type, Spectrum of Activity, Route of Administration, End User, and Region — Global Forecast to 2026.

[2] GlobalData. (2020). Antimicrobial resistance and biopharma market report.

[3] CDC. (2019). Antibiotic Resistance Threats in the United States.

[4] ClinicalTrials.gov. (2021). ERAP-3 Study Results.